Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT4R) Agonist Activities As Potential Agents against Alzheimer's Disease: The Design of Donecopride

Journal of Medicinal Chemistry

Volumn 58, Issue 7, 2015, Pages 3172-3187

  Rochais, Christophe ^a   Lecoutey, Cédric ^a   Gaven, Florence ^b,c   Giannoni, Patrizia ^b,c   Hamidouche, Katia ^d   Hedou, Damien ^a   Dubost, Emmanuelle ^a   Genest, David ^a   Yahiaoui, Samir ^a   Freret, Thomas ^d   Bouet, Valentine ^d   Dauphin, François ^d   De Oliveira Santos, Jana S ^a   Ballandonne, Céline ^a   Corvaisier, Sophie ^a,d   Malzert Fréon, Aurélie ^a   Legay, Remi ^a   Boulouard, Michel ^d   Claeysen, Sylvie ^b,c   Dallemagne, Patrick ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (2 METHYLCYCLOHEXYL)METHYL] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (3 PYRIDYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (4 PIPERIDYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE DIHYDROCHLORIDE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (4-PYRIDYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOBUTYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOHEPTYLMETHYL)]] 4 PIPERIDYLPROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOHEXYLETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOHEXYLMETHYL)] 4 PIPERIDYL]PROPAN 1 OL; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOHEXYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOHEXYLMETHYL)] 4 PIPERIDYL]PROPAN 1ONE OXIME; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOPENTYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 [1 (CYCLOPROPYLMETHYL)] 4 PIPERIDYL]PROPAN 1 ONE; 1 [[(4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BENZYL) 4 PIPERIDYL]]PROPAN 1 ONE; 4 AMINO 5 CHLORO N[[1 (CYCLOHEXYLMETHYL) 4 PIPERIDYL]METHYL] 2 METHOXYBENZAMIDE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONECOPRIDE; ETHYL 3 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 OXOPROPANOATE; NOOTROPIC AGENT; SEROTONIN 4 AGONIST; TERT BUTYL 4 [3 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 OXO PROPYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [3 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 OXOPROPYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [[(4 AMINO 5 CHLORO 2 METHOXYBENZOYL)AMINO]METHYL]PIPERIDINE 1 CARBOXYLATE; UNCLASSIFIED DRUG; [1 [(CYCLOHEXYLMETHYL) 4 PIPERIDYL]METHYL 4 AMINO 5 CHLORO 2 METHOXYBENZOATE; ANILINE DERIVATIVE; LIGAND; PIPERIDINE DERIVATIVE; SEROTONIN 4 RECEPTOR;

ACUTE TOXICITY; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; GUINEA PIG MODEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN SECRETION; STRUCTURE ACTIVITY RELATION; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; GUINEA PIG; HUMAN; INBRED MOUSE STRAIN; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; SHORT TERM MEMORY; TOXICITY TESTING; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ANIMALS; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; LIGANDS; MALE; MEMORY, SHORT-TERM; MICE, INBRED C57BL; MICE, INBRED STRAINS; MOLECULAR TARGETED THERAPY; PIPERIDINES; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN 5-HT4 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS, ACUTE;

EID: 84927773140     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00115     Document Type: Article

References (89)

1. Stelzmann, R. An English translation of Alzheimer's 1907 paper, "Über eine eigenartige erkankung der hirnrinde Clinical Anat. 1995, 1, 429 - 431
2. World Alzheimer Report 2013: the global economic impact of dementia. Alzheimer's Disease International Home Page. http://www.alz.co.uk (accessed December 12, 2014).
3. Mount, C.; Downton, C. Alzheimer disease: progress or profit? Nat. Med. 2006, 12, 780 - 784
4. Melnikova, I. Therapies for Alzheimer's disease Nat. Rev. Drug Discovery 2007, 6, 341 - 342
5. Rosini, M.; Simoni, E.; Minarini, A.; Melchiorre, C. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the diving forces Neurochem. Res. 2014, 39, 1914 - 1923
6. Citron, M. Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387 - 398
7. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711 - 715
8. Prati, F.; Uliassi, E.; Bolognesi, M. L. Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases MedChemComm 2014, 5, 853 - 861
9. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641 - 651
10. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523 - 6543
11. Espinoza-Fonseca, L. M. The benefits of the multi-target approach in drug design and discovery Bioorg. Med. Chem. 2006, 14, 896 - 897
12. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands Drug Discovery Today 2007, 12, 156 - 160
13. Korcsmáros, T.; Szalay, M. S.; Böde, C.; Kovács, I. A.; Csermely, P. How to design multi-target drugs Expert Opin. Drug Discovery 2007, 2, 799 - 808
14. Bolognesi, M.; Banzi, R. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease J. Med. Chem. 2007, 10, 4882 - 4897
15. Meunier, B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 2008, 41, 69 - 77
16. Cavalli, A.; Bolognesi, M. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347 - 372
17. Morphy, R.; Rankovic, Z. Multi-Target Drugs. Strategies and challenges for medicinal chemists. In The Practice of Medicinal Chemistry, 3rd ed; Wermuth, C. G., Ed.; Elsevier: Amsterdam, 2008; pp 549 - 571.
18. Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges Curr. Pharm. Des. 2009, 15, 587 - 600
19. Melchiorre, C.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V. Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy J. Med. Chem. 2010, 53, 5906 - 5914
20. Hopkins, A. L. Why design multi-target drugs? In Designing Multi-Target Drugs; Morphy, J. R.; Harris, C. J., Eds.; RCS Publishing: London, 2012; pp 394.
21. Lu, J. J.; Pan, W.; Hu, Y. J.; Wang, Y. T. Multi-target drugs: The trend of drug research and development PLoS One 2012, 7, e40262
22. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands J. Med. Chem. 2006, 49, 4961 - 4970
23. Schmitt, B.; Bernhardt, T.; Moeller, H. J.; Heuser, I.; Frolich, L. Combination therapy in Alzheimer's disease: a review of current evidence CNS Drugs 2004, 18, 827 - 844
24. Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer's disease Expert Opin. Ther. Pat. 2006, 16, 811 - 823
25. Zhang, H.-Y. One-compound-multiple-targets strategy to combat Alzheimer's disease FEBS Lett. 2005, 579, 5260 - 5264
26. Youdim, M. B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30 Curr. Alzheimer Res. 2006, 3, 541 - 550
27. Van der Schyf, C. J.; Geldenhuys, W. J.; Youdim, M. B. Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases Drugs Future 2006, 31, 447 - 460
28. Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multi-target-directed ligands in Alzheimer's disease treatment Curr. Med. Chem. 2011, 18, 4949 - 4975
29. Carmo Carreiras, M.; Mendes, E.; Jesus Perry, M.; Paula Francisco, A.; Marco-Contelles, J.; Carreiras, M.; Perry, M.; Francisco, A. The multifactorial nature of Alzheimer's disease for developing potential therapeutics Curr. Top. Med. Chem. 2013, 13, 1745 - 1770
30. Geldenhuys, W. J.; Van der Schyf, C. J. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders Expert Opin. Drug Discovery 2013, 8, 115 - 129
31. León, R.; Garcia, A. G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease Med. Res. Rev. 2013, 33, 139 - 189
32. Mao, F.; Yan, J.; Li, J.; Jia, X.; Miao, H.; Sun, Y.; Huang, L.; Li, X. New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol Org. Biomol. Chem. 2014, 12, 5936 - 5944
33. Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease Curr. Med. Chem. 2010, 17, 1825 - 1838
34. Agis-Torres, A.; Söllhuber, M.; Fernandez, M.; Sanchez-Montero, J. M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease Curr. Neuropharmacol. 2014, 12, 2 - 36
35. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V.; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase inhibitors based on a polyamine backbone for potential use against Alzheimer's disease J. Med. Chem. 1998, 41, 4186 - 4189
36. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A. 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: A dual function lead for Alzheimer's disease therapy J. Med. Chem. 2003, 46, 2279 - 2282
37. Bartolini, M.; Bertucci, C.; Carini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 2003, 65, 407 - 416
38. Bolognesi, M.; Andrisano, V.; Bartolini, M.; Banzi, R.; Melchiorre, C. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation J. Med. Chem. 2005, 48, 24 - 27
39. 3R and BACE 1 inhibitory activities Bioorg. Med. Chem. 2011, 19, 7158 - 7167
40. Li, Y.; Peng, P.; Tang, L.; Hu, Y.; Hu, Y.; Sheng, R. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy Bioorg. Med. Chem. 2014, 22, 4717 - 4725
41. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; Mcclymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 2008, 51, 4381 - 4384
42. Muñoz-Ruiz, P.; Rubio, L.; García-Palomero, E.; Dorronsoro, I.; del Monte-Millán, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Medina, M.; Martínez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease J. Med. Chem. 2005, 48, 7223 - 7233
43. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compounds against Alzheimer's disease J. Med. Chem. 2007, 50, 6446 - 6449
44. Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease Mini-Rev. Med. Chem. 2008, 8, 960 - 967
45. Liu, T.; Xia, Z.; Zhang, W.-W.; Xu, J.; Ge, X.-X.; Li, J.; Cui, Y.; Qiu, Z.-B.; Xu, J.; Xie, Q.; Wang, H.; Chen, H.-Z. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice Pharmacol., Biochem. Behav. 2013, 104, 138 - 143
46. Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment Neuropharmacology 2012, 62, 997 - 1003
47. Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young, S.; Hager, K.; Engel, J.; Münch, G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias Pharmacol. Ther. 2007, 113, 154 - 164
48. Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration Mini-Rev. Med. Chem. 2006, 6, 1269 - 1274
49. Bolognesi, M. L.; Rosini, M.; Andrisano, V.; Bartolini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C. MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond Curr. Pharm. Des. 2009, 15, 601 - 613
50. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 2009, 6, 152 - 162
51. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B.; Weinstock, M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 2002, 45, 5260 - 5279
52. Youdim, M. B.; Amit, T.; Bar-Am, O.; Weinreb, O.; Yogev-Falach, M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective- neurorescue drugs: ladostigil Neurotoxic. Res. 2006, 10, 181 - 192
53. Bolea, I.; Gella, A.; Unzeta, M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors J. Neural Transm. 2013, 120, 893 - 902
54. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases Curr. Med. Chem. 2011, 18, 4568 - 4587
55. Marco-Contelles, J.; León, R.; de Los Ríos, C.; Guglietta, A.; Terencio, J.; López, M. G.; García, A. G.; Villarroya, M. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 2006, 49, 7607 - 7610
56. Bartolini, M.; Pistolozzi, M.; Andrisano, V.; Egea, J.; López, M. G.; Iriepa, I.; Moraleda, I.; Gálvez, E.; Marco-Contelles, J.; Samadi, A. Chemical and pharmacological studies on enantiomerically pure p-methoxytacripyrines, promising multi-target-directed ligands for the treatment of Alzheimer's disease ChemMedChem. 2011, 6, 1990 - 1997
57. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. Engl. 2007, 46, 3689 - 3692
58. Lecoutey, C.; Hédou, D.; Freret, T.; Giannoni, P.; Gaven, F.; Since, M.; Bouet, V.; Ballandonne, C.; Corvaisier, S.; Malzert Fréon, A.; Mignani, S.; Cresteil, T.; Boulouard, M.; Claeysen, S.; Rochais, C.; Dallemagne, P. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E3825 - E3830
59. 4 receptor agonists, RS67333 and RS67506, in vitro and in vivo Br. J. Pharmacol. 1995, 115, 1387 - 1392
60. 4 receptor multi-target directed ligands MedChemComm 2012, 3, 627 - 634
61. 4 receptors in guinea pig and rat brain Br. J. Pharmacol. 1993, 109, 618 - 624
62. Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands J. Med. Chem. 2012, 55, 10282 - 10286
63. 4 receptor antagonists: application to the design of new potential single photon emission computed tomography (SPECT) tracers J. Med. Chem. 2012, 55, 9693 - 9707
64. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 2007, 318, 1258 - 1265
65. 4 receptors Br. J. Pharmacol. 2007, 150, 782 - 791
66. 4 partial agonist clinical candidates for the treatment of Alzheimer's disease J. Med. Chem. 2012, 55, 9240 - 9254
67. 4 receptors Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 39 - 51
68. Li, H.; Robertson, A. D.; Jensen, J. H. Very fast empirical prediction and rationalization of protein pKa values Proteins: Struct., Funct., Bioinf. 2005, 61, 704 - 721
69. Vagedes, P.; Rabenstein, B.; Åqvist, J.; Marelius, J.; Knapp, E.-W. The deacylation step of acetylcholinesterase: computer simulation studies J. Am. Chem. Soc. 2000, 122, 12254 - 12262
70. Fragkouli, A.; Papatheodoropoulos, C.; Georgopoulos, S.; Stamatakis, A.; Stylianopoulou, F.; Tsilibary, E. C.; Tzinia, A. K. Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over-expressing MMP9 J. Neurochem. 2012, 121, 239 - 251
71. 4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease Front. Aging Neurosci. 2013, 5, 96
72. 4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice Neurobiol. Aging 2013, 34, 1779 - 1789
73. 4 receptor ligands. WO 1994027965 A1, December 8, 1994.
74. Kawakita, T.; Kuroita, T.; Murozono, T.; Hakira, H.; Haga, K.; Ito, K.; Sonda, S.; Kawahara, T.; Asano, K. Benzoic acid compounds and use thereof as medicaments. US 5864039 A, January 26, 1999.
75. Sheldrick, G. M. A short history of SHELX Acta Crystallogr. 2008, A64, 112 - 122
76. Sheldrick, G. M. SHELXL2014; University of Göttingen: Göttingen, Germany, 2014.
77. Lowry, O. H.; Rosebrought, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent J. Biol. Chem. 1951, 193, 265 - 275
78. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetyl-cholinesterase activity Biochem. Pharmacol. 1961, 7, 91 - 95
79. Rosenberry, T. L.; Mallender, W. D.; Thomas, P. J.; Szegletes, T. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate Chem. Biol. Interact. 1999, 119-120, 85 - 97
80. Cheung, J.; Rudolph, M. J.; Burshteyn, F.; Cassidy, M. S.; Gary, E. N.; Love, J.; Franklin, M. C.; Height, J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands J. Med. Chem. 2012, 55, 10282 - 10286
81. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 1995, 245, 43 - 53
82. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727 - 748
83. Morpugo, C. A new design for the screening of CNS-active drugs in mice Arzneim.-Forsch./Drug Res. 1971, 11, 1727 - 1734
84. Freret, T.; Bouet, V.; Quiedeville, A.; Nee, G.; Dallemagne, P.; Rochais, C.; Boulouard, M. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice Behav. Brain. Res. 2012, 230, 304 - 308
85. Hooper, N.; Fraser, C.; Stone, T. Effect of purines analogues on spontaneous alternation in mice Psychopharmacology 1996, 123, 250 - 257
86. Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 1977, 229, 327 - 336
87. Aguila, B.; Coulbault, L.; Boulouard, M.; Léveillé, F.; Davis, A.; Tóth, G.; Borsodi, A.; Balboni, G.; Salvadori, S.; Jauzac, P.; Allouche, S. In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance Br. J. Pharmacol. 2007, 152, 1312 - 1324
88. Liu, L.; Duff, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse J. Visualized Exp. 2008, 21, 960 10.3791/960
89. Bourdin, J.; Desire, L.; Schweighoffer, F. Methods and tools for the therapy of neurodegenerative pathologies. WO2008009868, May 8, 2008.